Evaluating the competitive effects of corporate acquisitions and mergers #FTC-2018-0053-D-0016

Submission Number:
FTC-2018-0053-D-0016
Commenter:
Henry Waxman
Organization:
Waxman Strategies
State:
District of Columbia
Initiative Name:
Evaluating the competitive effects of corporate acquisitions and mergers
Dear Commissioner Simons, Thank you for the opportunity to comment on this topic. Attached, you will find my comments regarding acquisitions and mergers among the pharmaceutical supply chain. I am concerned with the consolidation in the supply chain, especially those involving Pharmacy Benefit Managers (PBMs), and how these mergers and acquisitions impact consumers and the prescription drug market. I encourage the FTC to study and analyze the horizontal and vertical consolidations that involve PBMs and other intermediaries, including payers, in the prescription drug market. Please do not hesitate to reach out with questions or comments. Regards, Henry Waxman